New hope for Hard-to-Treat lung cancer: experimental drug combo enters trial
NCT ID NCT07207395
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called JBI-802, either alone or with the immunotherapy pembrolizumab, in 30 adults with advanced lung cancer that has a specific genetic change (STK11 mutation). The main goals are to check safety and see if the treatment can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JBI-802 (an experimental drug) and pembrolizumab (an immunotherapy)
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of lung cancer that has few effective therapies.
- What could go wrong
- This is an early Phase 2 trial with only 30 participants, so results may not apply broadly. The drug combination may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Christ Hospital
RECRUITINGCincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer